New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors - Université d'Orléans Accéder directement au contenu
Article Dans Une Revue International Journal of Molecular Sciences Année : 2013

New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors

Résumé

Melatonin receptors have been studied for several decades. The low expression of the receptors in tissues led the scientific community to find a substitute for the natural hormone melatonin, the agonist 2-[125I]-iodomelatonin. Using the agonist, several hundreds of studies were conducted, including the discovery of agonists and antagonists for the receptors and minute details about their molecular behavior. Recently, we attempted to expand the panel of radioligands available for studying the melatonin receptors by using the newly discovered compounds SD6, DIV880, and S70254. These compounds were characterized for their affinities to the hMT1 and hMT2 recombinant receptors and their functionality in the classical GTPS system. SD6 is a full agonist, equilibrated between the receptor isoforms, whereas S70254 and DIV880 are only partial MT2 agonists, with Ki in the low nanomolar range while they have no affinity to MT1 receptors. These new tools will hopefully allow for additions to the current body of information on the native localization of the receptor isoforms in tissues.

Dates et versions

hal-03404079 , version 1 (26-10-2021)

Identifiants

Citer

Christian Legros, U. Matthey, T. Grelak, S. Pedragona-Moreau, W. Hassler, et al.. New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors. International Journal of Molecular Sciences, 2013, 14 (5), pp.8948 - 62. ⟨10.3390/ijms14058948⟩. ⟨hal-03404079⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More